http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 16:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jul+15/26774797.html si-local-file:///var/storage/secattach/20260715/26774797.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jul+15/26774797.html Wed, 15 Jul 2026 16:57:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jul+15/26774797.html si-local-file:///var/storage/secattach/20260715/26774797.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jul+15/26774797.html Wed, 15 Jul 2026 16:57:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jul+15/26774797.html si-local-file:///var/storage/secattach/20260715/26774797.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jul+15/26774797.html Wed, 15 Jul 2026 16:57:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/Analyst+PT+Change/Ascendis+Pharma+%28ASND%29+PT+Raised+to+%24306+at+BofA+Securities/26764181.html <p>BofA Securities analyst Tazeen Ahmad raised the price target on Ascendis Pharma (NASDAQ: ASND) to $306.00 (from $288.00) while maintaining a Buy rating.</p><p>The analyst comments "ASND reported 1Q26 Yorvipath revenues of €196.9mn, with mgmt attributing the softer quarter primarily to typical insurance seasonality resulting in coverage disruptions and increased free-drug utilization. Mgmt commented these impacts had normalized by quarter-end and reiterated confidence in achieving >€1bn of Yorvipath revenue in FY26. For 2Q26, we model Yorvipath revenues of €252mn (cons: €247mn). On the 2Q call, we look for additional color on the expected sales recovery following the seasonally impacted 1Q, particularly http://www.streetinsider.com/Analyst+PT+Change/Ascendis+Pharma+%28ASND%29+PT+Raised+to+%24306+at+BofA+Securities/26764181.html Tue, 14 Jul 2026 06:03:00 -0400 ASND http://www.streetinsider.com/Analyst+Comments/Ascendis+Pharma+%28ASND%29+PT+Raised+to+%24306+at+BofA+Securities/26764181.html <p>BofA Securities analyst Tazeen Ahmad raised the price target on Ascendis Pharma (NASDAQ: ASND) to $306.00 (from $288.00) while maintaining a Buy rating.</p><p>The analyst comments "ASND reported 1Q26 Yorvipath revenues of €196.9mn, with mgmt attributing the softer quarter primarily to typical insurance seasonality resulting in coverage disruptions and increased free-drug utilization. Mgmt commented these impacts had normalized by quarter-end and reiterated confidence in achieving >€1bn of Yorvipath revenue in FY26. For 2Q26, we model Yorvipath revenues of €252mn (cons: €247mn). On the 2Q call, we look for additional color on the expected sales recovery following the seasonally impacted 1Q, particularly http://www.streetinsider.com/Analyst+Comments/Ascendis+Pharma+%28ASND%29+PT+Raised+to+%24306+at+BofA+Securities/26764181.html Tue, 14 Jul 2026 06:03:00 -0400 ASND http://www.streetinsider.com/Analyst+PT+Change/Ascendis+Pharma+%28ASND%29+PT+Raised+to+%24280+at+RBC+Capital/26738649.html RBC Capital analyst Luca Issi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $280.00 (from $275.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Ascendis+Pharma+%28ASND%29+PT+Raised+to+%24280+at+RBC+Capital/26738649.html Tue, 07 Jul 2026 07:59:22 -0400 ASND http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+30/26713563.html si-local-file:///var/storage/secattach/20260630/26713563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+30/26713563.html Tue, 30 Jun 2026 16:05:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+30/26713563.html si-local-file:///var/storage/secattach/20260630/26713563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+30/26713563.html Tue, 30 Jun 2026 16:05:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+30/26713563.html si-local-file:///var/storage/secattach/20260630/26713563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+30/26713563.html Tue, 30 Jun 2026 16:05:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Press+Releases/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html <ul type="disc"><li style="list-style-position:inside; margin-bottom:6pt; text-align:center;"><em>Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104</em></li><li style="list-style-position:inside; margin-bottom:12pt; text-align:center;"><em>Greater improvements observed in children with preexisting genu varum (leg bowing)</em></li></ul> <p>COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements http://www.streetinsider.com/Globe+Newswire/Children+with+Achondroplasia+Treated+with+TransCon+CNP+Showed+Continued+Improvements+in+Lower+Extremity+Alignment+at+Week+104+of+the+Pivotal+ApproaCH+Trial/26710198.html Tue, 30 Jun 2026 08:30:00 -0400 A.28176729 ASND O.05704847 O.26395000 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+29/26706394.html si-local-file:///var/storage/secattach/20260629/26706394.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+29/26706394.html Mon, 29 Jun 2026 16:05:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+29/26706394.html si-local-file:///var/storage/secattach/20260629/26706394.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+29/26706394.html Mon, 29 Jun 2026 16:05:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+29/26706394.html si-local-file:///var/storage/secattach/20260629/26706394.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+29/26706394.html Mon, 29 Jun 2026 16:05:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/Index+Changes/Ascendis+Pharma+added+to+Russell+1000+and+other+indexes/26698595.html <p>Ascendis Pharma A/S (Nasdaq: ASND) has been added to four Russell U.S. Indexes as part of the 2026 semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.</p> <p>The Copenhagen-based biopharmaceutical company was included in the Russell 3000®, Russell 1000®, Russell 2500®, and Russell Midcap® indexes. Inclusion in the Russell 1000®, Russell 2500®, and Russell Midcap® indexes also results in automatic inclusion in the corresponding growth and value style indexes.</p> <p>The Russell 3000® tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. The Russell 1000® comprises the 1,000 largest securities within http://www.streetinsider.com/Index+Changes/Ascendis+Pharma+added+to+Russell+1000+and+other+indexes/26698595.html Fri, 26 Jun 2026 16:01:11 -0400 ASND O.05704847 http://www.streetinsider.com/Index+Changes/Ascendis+Pharma+added+to+Russell+1000+and+other+indexes/26698595.html <p>Ascendis Pharma A/S (Nasdaq: ASND) has been added to four Russell U.S. Indexes as part of the 2026 semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.</p> <p>The Copenhagen-based biopharmaceutical company was included in the Russell 3000®, Russell 1000®, Russell 2500®, and Russell Midcap® indexes. Inclusion in the Russell 1000®, Russell 2500®, and Russell Midcap® indexes also results in automatic inclusion in the corresponding growth and value style indexes.</p> <p>The Russell 3000® tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. The Russell 1000® comprises the 1,000 largest securities within http://www.streetinsider.com/Index+Changes/Ascendis+Pharma+added+to+Russell+1000+and+other+indexes/26698595.html Fri, 26 Jun 2026 16:01:11 -0400 ASND O.05704847 http://www.streetinsider.com/Press+Releases/Ascendis+Joins+Multiple+Russell+U.S.+Indexes%2C+Including+the+Russell+3000%C2%AE%2C+Russell+1000%C2%AE%2C+Russell+2500%C2%AE+and+Russell+Midcap%C2%AE/26698593.html <p>COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.</p> <p>The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest http://www.streetinsider.com/Press+Releases/Ascendis+Joins+Multiple+Russell+U.S.+Indexes%2C+Including+the+Russell+3000%C2%AE%2C+Russell+1000%C2%AE%2C+Russell+2500%C2%AE+and+Russell+Midcap%C2%AE/26698593.html Fri, 26 Jun 2026 16:01:00 -0400 ASND O.05704847 http://www.streetinsider.com/Press+Releases/Ascendis+Joins+Multiple+Russell+U.S.+Indexes%2C+Including+the+Russell+3000%C2%AE%2C+Russell+1000%C2%AE%2C+Russell+2500%C2%AE+and+Russell+Midcap%C2%AE/26698593.html <p>COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.</p> <p>The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest http://www.streetinsider.com/Press+Releases/Ascendis+Joins+Multiple+Russell+U.S.+Indexes%2C+Including+the+Russell+3000%C2%AE%2C+Russell+1000%C2%AE%2C+Russell+2500%C2%AE+and+Russell+Midcap%C2%AE/26698593.html Fri, 26 Jun 2026 16:01:00 -0400 ASND O.05704847 http://www.streetinsider.com/Globe+Newswire/Ascendis+Joins+Multiple+Russell+U.S.+Indexes%2C+Including+the+Russell+3000%C2%AE%2C+Russell+1000%C2%AE%2C+Russell+2500%C2%AE+and+Russell+Midcap%C2%AE/26698593.html <p>COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.</p> <p>The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest http://www.streetinsider.com/Globe+Newswire/Ascendis+Joins+Multiple+Russell+U.S.+Indexes%2C+Including+the+Russell+3000%C2%AE%2C+Russell+1000%C2%AE%2C+Russell+2500%C2%AE+and+Russell+Midcap%C2%AE/26698593.html Fri, 26 Jun 2026 16:01:00 -0400 ASND O.05704847